### Index

**A**
- Accidental injury, 9
- Actigraphy, 197, 201, 204, 206
  - activity monitors, 209
  - assessments, 209
  - awakening response, 211
  - calculation, sleep/wakefulness periods, 209–210
  - clinical advantages, 209
  - clinical/sleep laboratory evaluations, 212
  - clinical utility, 210
  - in conjunction, with sleep diary, 212
  - description, 209
  - inactivity periods, 210
  - in-home monitoring, 210
  - “lights out” or “awakening”, 209
  - movement and autonomic variability, during sleep, 212
  - person with insomnia complaints, 210, 211
  - PTSD checklist, 212
  - recording device, 209–211
  - subjective assessments, 212
- Active system consolidation theory, 266
- Adjunctive IRT/waitlist control, 285
- Adrenaline storm, 350
- Affect Control Scale, 297
- Age regression techniques, 319
- Aggression, 9
- Agomelatine, 330
- Amygdala
  - eye movement desensitization and reprocessing, 158
  - in fear learning and emotional responses, 157
  - hyperresponsive in individuals with PTSD, 114, 115
  - size reduction and cognition impairment, 157
  - structural abnormalities, 157
  - volumes, pediatric PTSD, 157
- Anisomycin
  - intervention, memory consolidation process, 128
  - memory reconsolidation process, intervention, 135
- Antecedents, Beliefs, Consequences (A-B-C), 293
- Anterior cingulate cortex (ACC)
  - accumulating structural studies, 158
  - emotional and cognitive functions, 158
  - factors, affecting grey matter structure, 158
  - hyperactivity, 158
  - PCC, 158
  - white matter integrity, 158
- Anticonvulsants, 330
  - divalproex, 336
  - gabapentin, 335
  - glutamate neurotransmission, inhibition of, 335
  - lamotrigine, 335
  - levetiracetam, 336
- localization-related epilepsy, 335
  - pregabalin, 337
  - tiagabine, 336
  - topiramate, 336
- Antipsychotics
  - aripiprazole, 338
  - clozapine, 338
  - levomepromazine, 338
  - olanzapine, 338, 342
  - quetiapine, 338
  - risperidone, 337
  - thioridazine, 338
- Antonovsky’s Life Crises Scale, 390
- Anxiety disorders, 80, 247
- Aripiprazole, 338
- Arousal
  - attention and working memory tasks, 228
  - inverted U-shape, LC activity and task performance, 227, 228
  - and LC-system, cortisol role, 229
  - quantitative EEG findings, 230
  - sleep and wakefulness, 227
- Assessment methods, sleep disturbances, 197
  - advantages, 194
  - Berlin Questionnaire, 197
  - CAPS, 195
  - DDNSI, 196
  - ISI, 196
  - prospective
    - actigraphy, 197
    - questionnaires, 197
    - sleep diaries, 197
    - wearable devices, 197
  - PSQI, 196
  - STOP-BANG, 196
- Assessment strategy
  - consistency, 16
  - dissociation, 187
  - guilt, 188
  - instruments, 180
  - Land Combat Study, 15
  - methodology, 16
  - PC-PTSD scores, 16
  - PDHA, 15, 16
  - PSS cut-off score, 16
  - PTSD prevalence, in military, 16, 17
  - and sample characteristics, 16
  - structured interviews (see Structured interviews, assessment of PTSD)
    - timing and population, 15
    - trauma exposure measure, 180
    - trauma-related sleep disturbance, 188
  - Autonomic hyperarousal, 317
  - Autonomic nervous system, 253, 254
B
Battlemind training system, 52, 53
Beck Anxiety Inventory (BAI), 386
Behavioral Needs Assessment Survey, 60
Benzodiazepines, 325, 328, 339, 341
Berlin Questionnaire, 197
Borderline personality disorder (BPD), 80
Brain-derived neurotrophic factor (BDNF), 91
Brain imaging, 204
Brain structural abnormalities, in PTSD, 145–156
amygdala, 157, 158
CAT and MRI, 145
cerebellum and subcortical nuclei, 161
cingulate cortex, 158
corpus callosum, 161
DTI and FA technique, 145
in emotion regulation, 162
frontal lobe, 160
global volumes, 159, 160
hippocampus, 145, 156, 157, 162
insomnia severity, 162
insular cortex, 160
longitudinal investigations, 162
occipital lobe, 161
parahippocampal gyr (PHG), 160
parietal lobe, 161
PFC, 158, 159
sleep, 161
structural differences, 145
structural MRI studies
on adult PTSD, 145–153
on pediatric PTSD, 145, 154–156
temporal lobe, 160
Brief Psychiatric Rating Scale (BPRS), 386
Buspirone, 340
C
Cannabis, 341
for sleep problems, 341
and synthetic cannabinoids, 341
use, for PTSD, 341
Central sleep apnea (CSA), 244
Centre for Rehabilitation of Torture Victims (CRTV), 396
Challenging Questions Worksheet (CQW), 293, 294
Child abuse survivors (CPT-SA), 295, 296
Child and Adolescent Trauma Treatment and Services Project (CATS), 366
Chi-square test, 376
Circadian scarring, 70, 74
Citalopram, 327
Civilian Mississippi Scale (CMS), 185
Classroom-Based Intervention (CBI), 367
Clinical Global Impression of Change (CGIC), 352, 353
Clinician-Administered PTSD Scale (CAPS), 91, 180–182, 184, 187, 195, 295, 299, 352, 390
Clonidine, 326, 328, 338, 339
Clozapine, 338
Cognitive-affective bridge, 319
Cognitive-behavioral interventions, 304
Cognitive behavioral social rhythm therapy (CBSRT), 285
Cognitive behavioral therapy (CBT), 81, 299
Cognitive behavioral therapy for insomnia (CBT-I), 284, 285, 306
integrative treatments, 285
nightmare treatments
adjunctive IRT/waitlist control, 285
ERRT, 284, 285
IRT, 284
nonresponders, 284
psychoeducation, progressive muscle relaxation and sleep hygiene, 284
randomized parallel group study, 284
sleep restriction, 284
primary and secondary insomnia, 283
in PTSD treatment
combine sleep interventions, 285
CPT, 285
nightmare rescription combined with, 285
RCT, 284, 285
self-reported sleep questionnaires and daily monitoring, 285
severity and sleep parameters, 284
sleep prior, 285
Cognitive Distortion Scale, 297
Cognitive elements (CE), 403
Cognitive-experiential dream model (CEDM), 311, 312, 315
Cognitive processing therapy-cognitive (CPT-C), 278, 295
Cognitive processing therapy (CPT), 296, 297, 311, 312
comorbid symptoms
Beck Depression Inventory-II, 297
chronic health problems, 297
Cognitive Distortion Scale, 297
CPT-C, 296
MA, 296
National Comorbidity Study, 296
PE, 296
Pennebaker Inventory of Limbic Languidness, 297
physical health symptoms, 297
pre- to posttreatment, 297
problematic cognitions, 297
PTSD treatment program, 297
RCTs, 296
Spielberger State-Trait Anxiety Inventory, 297
State-Trait Anger Expression Inventory, 297
Trauma-Related Guilt Inventory, 296, 297
trauma-related symptoms, 296
dismanting, 295
evidence-based interventions, PTSD, 278
modifications, 295, 296
pharmacological intervention, 299
principles, 294
PTSD and depression, 296
seminal studies, 295
structure, 293, 294
and trauma-related sleep disturbance, 297, 298
Cognitive restructuring, 320
Combat disorders, 303, 304, 306, 307
Combat-exposed PTSD
alcohol misuse, 18
categorization approach, 18
and declarative memories, 268–270
exposure variables, 17
malevolent environment, 18
Millennium Cohort Study, 17
NDR, 315
negative mental health, 18
suicidal ideation, 78
suicide, in Vietnam marines, 78
suicide rates, in PTSD, 79
testing for mediation, 17
trauma, 81
types, 17
variables, 19, 20
war in Croatia, 17
war zone stressors, 17
Community-based studies, 388
The Clinical Analysis Questionnaire CAQ-A and CAQ-B, 387
Jerusalem Longitudinal Study (see Jerusalem Community Health Study)
limitations, 388
PSQI, 388
sleepiness, 387
survivor’s syndrome, 387
Comorbidity
common medical, 243, 246
medical and psychiatric, 249
prevalence rates, 247
psychiatrics, 307
PTSD and SDB, 247
Complex insomnia, 246, 250
Composite International Diagnostic Interview (CIDI), 182
Comprehensive Soldier Fitness, 53
Computerized axial tomography (CAT), 145
Connor-Davidson Resilience Scale (CD-RISC), 54, 55
Consolidation process, memory
anisomycin, intervention, 128
behaviors dependents, 128
corticosterone, early post-stressor intervention, 130, 131
cortisol-impaired consolidation processes, 137, 138
mTOR, early post-stressor microinjection, 128, 129
PKMζ, early post-stressor microinjection, 130
propranolol, early post-stressor intervention, 132, 133
SD, post-stressor intervention, 133
sleep deprivation-impaired consolidation processes, 139
Continuous positive airway pressure (CPAP) device, 205, 289
Coping mechanisms, 81
Cornell Medical Index (CMI), 389
Corticosterone
animal studies, 140
dosage, 130, 131
early post-stressor intervention, 130
neuromodulator stress hormone, 128
post-reminder administration, 135–137
Corticotropin-releasing hormone receptor 1 (CRHR1), 91
Cortisol, 340
Cortisol-impaired consolidation processes, 137, 138
Countermeasures, military operational, 72, 74
Couples counseling, 294
Cyproheptadine, 340

D
Davidson Trauma Scale (DTS), 183, 184, 186, 195
Daytime sleepiness, 29, 30
Declarative memories, 266–270
consolidation
encoding following sleep, 267
REM, 267
SWS, 266, 267
and sleep in combat-related PTSD
active consolidation process, 268
combat veterans, 268
diagnosed, 269
disruptions in SWS/REM sleep, 268, 269
healthy control group and GH secretion, 269
impairments, 268
mechanisms, 269
neuromaging studies, 268
neuropsychology, 270
polysomnographically monitored sleep, 269
relationship between sleep and performance, 269
retention ability, 268
verbal memory performance, 269
Deep NREM (SWS), 266, 267
Deepening techniques, 320, 321
Default mode network (DMN), 317
Depressive disorders
benzodiazepines effect, 339
citalopram effect, 327
cyproheptadine, 340
DSM-5, 325
duloxetine effect, 327
fluvoxamine effect, 327
mirtazapine, 330
moclobemide, 329
paroxetine effect, 326
phenelzine, 329
PTSD and TBI, 28
risperidone, 337
SNRIs effect, 327
SSRIs, 338
TCAs effect, 328
Detailed Assessment of Posttraumatic Stress (DAPS), 184, 187
Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5), 277
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV), 297, 396
Diffusion tensor imaging (DTI)
in corpus callosum, 161
in frontal lobe, 160
measurements, 145
parietal lobe, 161
in PCC, 158
PFC, white matter connectivity in PTSD, 159
on white matter integrity, ACC, 158
Disrupted sleep
clinical data, 227
fear conditioning and extinction, 229
for fear extinction consolidation, 229, 230
memory consolidation, 229
objective, 227
Disruptive nocturnal behaviors (DNB)
characteristic finding, 218
disease course, 218
in nocturnal epilepsy, 221
onset/precipitating factors, 217
and patient’s nightmares, 218
PSQI-A, 217
self-report measures, 196
sleep disturbances, 215
symptoms, 218
and TSD, 215
with vivid dreams, 219
Dissociation
definition, 187
DES, 187
DSPS, 187
MDI, 187, 188
subscales, 187
Dissociative Experiences Scale (DES), 187
Dissociative Subtype of PTSD Scale (DSPS), 187
Distressing dreams, 8, 395
Disturbing Dream and Nightmare Severity Index (DDNSI), 196
Divalproex, 336
Dopamine
- implications, 172
- plasma and urinary dopamine levels, 172
- 9-repetition (9R) allele, 172
- SPECT, imaging, 172
Dopamine D2 receptor gene (DRD2), 99
Doxazosin vs prazosin, 353
DRAW steps, 312–314
Dream coding system, 397, 398
Dreaming, 303, 304, 306, 395, 398, 405, 408
Dream substitution, 319
Duloxetine, 327

E
Early detection, PTSD, 262
Ego-strengthening, 319
Electrocardiogram (ECG)
- bio-electric heart activity, 255
- clinical and health HRV assessments, 255, 256
- recording, different skin positions, 255
- standard extensive cardiological assessments, 255
Emotional processing, 312
Enunciation, 398, 403, 405,  (see also Psychoanalytic enunciation analysis (PEA))
Epworth Sleepiness Scale, 205
ERASE-stress, 367
Escitalopram, 327
Ethnic cleansing, 396
European Study of the Epidemiology of Mental Disorders (ESEMED), 78
Evidence-based treatments (EBTs), 311
PTSD
- CPT, 278
- EMDR, 278
- evidence-based interventions, 277–278
- PE, 277–278
Exact replicas, 395
Exposure therapy, 11
Exposure, relaxation and rescripting therapy (ERRT), 284, 285, 306
- community sample, traumatized adults, 283
- exposure and trauma-related themes, 283
- IRET, 283
- mechanisms, 283
- participants, 283
- personal nightmare scripts, 283
- physiological responses to nightmare, 283
- RCTs, 283
- rescripting and imagery rehearsal, 283
- sleep quality and quantity, 283
- trauma-related nightmares, 283
Exposures, 10
Extinction. See Fear conditioning
Eye movement desensitization and reprocessing (EMDR), 278

F
False memory syndrome, 323
Family therapy, 367
Fatigue, 26, 27
- alertness, sleep-deprived service members, 72
- sleep deprivation, 70
- sleeping conditions, 72
Fear conditioning, 9, 229
- context, 112
- healthy humans, 111
- neuroimaging, 111
- neutral CS, 111
- Pavlovian, 111
- rodent models, 111
- structural MRIs, 112
Fear extinction, 229
Flow limitation event (FLE), 243
Fluoxetine, 326, 327, 329
Fluvoxamine, 327
Forced displacement, 365
Functional MRI studies, 267
Functional neuroimaging studies, PTSD, 113

G
Gabapentin, 335
γ-Aminobutyric acid receptor (GABAAR)
- distribution volume, in Vietnam veterans, 171
- functional deficits, in brain regions, 171, 172
- human pharmacologic studies, 171
Gender differences, PTSD
- cognitive appraisal, 38
- combat exposure, 34, 36
- coping styles, 39
- masculinity and femininity, 37
- MST, 36
- response to treatment, 40
- sleep, 38
Gene-environment interplay, 90
Genome-wide association studies (GWAS)
PTSD, 91–96
- sleep phenotypes, 99
Guanfacine, 338, 339

H
Hamilton Depression Scale (HAM-21), 386
Healthy sleep, 265
- clinical neuropsychological perspective, 265
- and declarative memories (see Declarative memories)
- encoding and consolidation, 265
Heart periods, 258
- calculations, 257
- cardiovascular circulation, 254
- chambers, 254
- description, 257
- electrical innervation, 254, 255
- electrophysiological activity, in surrounding tissue, 255
- frequency domain measures, 258, 259
- nonlinear measures, 259
- phases, heart cycle, 254
- time domain methods, 257, 258
- time-frequency domain methods, 259
Heart rate variability (HRV)
- ECG recordings, 255
- frequency distribution, 258
- frequency domain measures, 258
- NN intervals, 257
- nonlinear measures, 259
- power values, 259
- in PTSD, 259, 260
- “Hidden observer” technique, 320
Index

Hippocampus
- abnormal activation, 145
- CBT, 157
description, 118
- fearful vs. neutral faces, 119
functional MRI findings, 156
functional neuroimaging studies, 119
in learning and memory processing, 145
nonemotional tasks, 119
PTSD researchers, 118
statistical approaches, 120
structural characteristics, 157
structural MRI studies, 157
subdivisions, size of, 156
trauma-related stimuli, 119
trauma-unrelated emotional stimuli, 119

Holocaust exposure
- and psychopathology, 381, 382
- and sleep disturbances, 382
Home imagery practice, 304
Hydroxyzine, 353
Hyperarousal, 29, 30
Hypnosis, 318–322
- combat veterans with PTSD, 319
contra-indications, 323
definition, 317
DMN, described, 318
hypnotizability, 318
- for insomnia
  - beneficial effects, 319
  - classic CBT, 320
  - RCTs, 318
  - rumination, 319
  - testing, hypnotizability, 319
- for nightmares, 319
for PTSD, 320
techniques
  - debriefing, 320
  - deepening, 321
  - induction, 320
  - recorded hypnotic approaches, 321, 322
  - relaxation, 322
  - ruminations, 321
  - treatment plan, 321
  - theoretical underpinnings, 318
  - trance logic, 318
  - trance work, for insomnia, 322
  - treatment, 299
Hypnotherapy
- cognitive, 320
- for insomnia, 318, 319
Hypnotic suggestion technique, 320–322
Hypnotizability, 318

Insomnia
- childhood sexual abuse, 202
- collateral information, 209
definition, 202
evaluation, 209
factors, 59
MHAT reports, 60
in military combat, 202
in natural disasters, 202
primary symptoms, 50
PTSD and TBI, 28
self-report measures, 59, 196
sleep efficiency, classification, 60
Spielman’s model, 60
trauma, 202
types, 202
Insomnia Severity Index (ISI), 196
Insufficient sleep, 69, 70, 72, 74
Insula
- comorbid depression, 120
- emotional tasks, 120
- hyperarousal symptoms/emotional numbing symptoms, 120
- trauma-exposed controls, 120
- trauma-unexposed participants, 120
- trauma-unrelated emotional stimuli, 120

Imagery rehearsal therapy (IRT), 284, 304–306, 311
- characteristics, 303, 307
- chronic nightmares, 303
contra-indications, 304, 305
dismantling, 307
dreams, 303
empirical evidence, 306, 307
- group/individual format, 279
history, 304
hypermetabolism, 303
indications, 304, 305
- insomnia, 307
- interventions targeting sleep disturbance in military personnel, 279–282
- neurobiological mechanisms, 303
- nightmare and trauma-related material, 279, 303
- non-pharmacologic approaches, 307
- nonrandomized trials, 279, 283
- optimal dosage, 307
- pharmacologic and cognitive-behavioral therapies, 303, 307
- Pittsburgh Sleep Quality Index, 279
- primary outcomes, 307
- PTSD, 279, 303, 307
- RCTs, 279, 307
- REM sleep, 303
- short-term intervention, 307
- standardized treatment approach, 307
- trauma-focused therapy, 307
- treatment
  - avoidance, adherence and adverse effects, 305
  - CBTI, 306
  - components, 304, 305
delivery, duration and format, 306
ERRT, 306
patient instructions, 304
protocol variants, 305, 306
rationale, 304
sleep dynamic therapy, 306
sleep/trauma-focused techniques, 306
veterans, 303, 307
Imagery rescripting and exposure therapy (IRET), 283
Imaging methods, 112, 113
Immediate early genes (IEGs), 267
Impact of Event Scale (IES), 184, 195, 386
Impaired memory
- attention, 268
- consolidation and LTP, 267
  - at night, 270
  - in PTSD, 265
Indirect exposure, 366, 369
Induction technique, 320, 321
Inexpensive and cost-effective formats, IRT, 306
Inner personality dynamics, 313

I

1

2
Interaction field (IAF), 403
International Classification of Sleep Disorders (ICSD-2), 277
Interpersonal and social rhythm therapy (IPSRT), 285
Irritability, 30

Jerusalem Community Health Study
interview schedule, 390, 391
mortality, medical and social parameters, 390
OARS medical checklist, 390
questionnaire, 389
WMHS, 390

KIDNET, 366, 367

Lamotrigine, 335
Land Combat Study, 15
Levetiracetam, 336
Levomepromazine, 338
Life Events Checklist (LEC), 375
Light NREM sleep, 266, 267
Loco time motion (LTM), 400, 403
Locus coeruleus (LC) system
and arousal, cortisol role, 227, 229
attention/general information processing speed, 228
in REM sleep, 228
tonic LC activity, levels, 227, 228
Long-term depression (LTD) process, 266
Long-term potentiation (LTP) process, 266

Magnetic resonance imaging (MRI), 204
amygdala, structural properties, 157
brain structural properties, 145
hippocampus, 145, 157
Mammalian target of rapamycin (mTOR), 128
Medial prefrontal cortex (mPFC)
aversive vs. neutral pictures, 118
dACC, 115, 118
facial expressions, 117
imaging studies, 116
memory paradigm, 117
nonemotional go/no-go task, 118
PTSD and trauma-exposed healthy control participants, 115
structures, 115
traumatic/stressful scripts, PET, 117
ventral, 115
vmPFC regions, 118
Medical disorders, 307
Memory, 128, 135
consolidation, 127, (see also Consolidation process, memory)
deficits, 29
“erasing” memory, 137
experimental pharmacological interventions, 128
pharmacological disruption, 127
reconsolidation, 128 (see also Reconsolidation process, memory)
sleep- and declarative, 265
traces, 266
traumatic events, 127
Memory consolidation, 266, 267
declarative memories
encoding following sleep, 267
REM, 267
SWS, 266–267
process of, 265
Memory processing
sleep acts, 270
sleep in healthy individuals, 265
sleep in PTSD, 268
waking and learning, 266
Mental Health Advisory Team (MHAT) reports, 15, 61–67
Joint-MHAT-7
energy drinks, 64
factors impacting sleep, 65
medication usage, 64
samples, Air Force and Navy personnel, 64
sleep and deployment concerns, 65
sleep management recommendations, 65
Joint-MHAT-8
leadership and sleep, 65
sleep management recommendations, 66
sleep-related findings, 65
MHAT-9, 66
MHAT-I, 60
MHAT-II, 60
MHAT-III, 60
MHAT-IV, 61
MHAT-V
assessment measures, 61
medications, 62
research, 67
sleep and behavioral health problems, 61
sleep and performance, 61
sleep deprivation, 61
sleep management recommendations, 62, 64
Soldier Combat and Well-Being Model, 62
MHAT-VI
goals, 62
medication use, 63, 64
sleep and deployment concerns, 64
Mifepristone, 340
Military deployment, 59
battle-related sleep problems, 59
perpetuating factors, 59
predisposing factors, 59
sleep disturbance (see Sleep disturbance, military deployment)
Military operations, 70–73
countermeasures, 72
insufficient sleep
and circadian rhythmicity, 70
multifaceted effects, 70, 71
sleep deprivation, 70
normal sleep, 69
sleep patterns
average age, officers, 70
components, good sleep, 70
daily sleep duration, 70, 71
factors, 70, 72, 73
first-order and second-order, 72
shiftwork, 70
sleeping conditions, 72
Military personnel, 50–52
natural history, types and causes, sleep disturbance, 55
resiliency (see Psychological resiliency, in military)
sleep disturbance, incidence and impact
combat operations, 51
Index

417

during deployment, 50
insomnia, incident rate, 50
J-MHAT 7 reports, 51
MHAT V and VI reports, 51
Millennium Cohort Study, 50
PHQ, 51
sleep management system, 52
stressors, 51
sources of disruption, 49
Military sexual trauma (MST)
combat stressors, 34
development risk, 34
experiencing, 34
gender differences, in mental health outcomes, 36
Military veterans, 303, 306
Millennium Cohort Study, 15, 17
Minimal attention (MA) waiting list, 295
Minnesota Multiphasic Personality Inventory-2 (MMPI-2), 186
Mirtazapine, 330, 342
Mississippi Scale for Combat-Related PTSD (M-PTSD), 195
Moclobemide, 329
Molecular genetic studies
PTSD, 91
sleep phenotypes, 97–99
Monoamine oxidase inhibitors (MAOIs)
moclobemide, 329
phenelzine, 328, 329
tranylcypromine, 328
Montreal Cognitive Assessment (MoCA), 354
Mood disorders, 79
Moser method, 401–405
Multiple channel exposure therapy, 285
Multiscale Dissociation Inventory (MDI), 187
“Myth of the warrior”, 72

N
Narrative Exposure Therapy (NET), 366
National Comorbidity Study, 296
National Vietnam Veterans Readjustment Study (NVVRS)
combat exposure and PTSD, 17
in-depth diagnostic interviews, 14
structural equation modeling, 19
war zone stressors, 17
Nefazodone, 330
New Soldier Study (NSS), 96
Nightmare deconstruction and reprocessing (NDR), 312–314
combat-related PTSD, 315
CPT, 311
developing PTSD treatments, 311
distressing dream, 314
DRAW steps, 314
dream reconstruction, 315
EBTs, 311
extreme discomfort, 315
IRT, 311
origins and preliminary findings, 311–312
PE, 311
psychoeducation, 314
psychotherapy, 311
REM and REM sleep, 311
RG, 314, 315
structure
assessment, 312
exposure and deconstruction, 312
meaning making and reprocessing, 312–313
psychoeducation on PTSD, 312
reconstruction and rehearsal, 313–314
SUDS, 312
symptom of PTSD, 311
US Army infantry veteran, 314
Nightmares, 279–283, 319, 395–397
actigraphy, evaluation, 209
acute and chronic stress, 238
adaptations, 238
amygdala, 239
anxiety-provoking, 305
anxiety spectrum disorders, 233
arousals, 233, 234, 238
attentive immobility, 239
autonomic signature, 233
c-fos, 239
characteristics, 303
chronic, 303, 304
circadian effects, 236
classification, 203
clinical course, 218
in combat veterans, 303, 307
consciousness, 239
content/type, 307
DDNSI, 196
and DEB, 219
definition, 203
disorder, 221
and disturbed sleep, 304
and DNB, 218
dream content, 221
dream reports, 234
educational component, 304
electrooculogram (EOG), 234
emotional elements, 203
fear bradycardia, 239
freezing, 239
frequency and intensity, 303, 304
gamma-band EEG, 239, 240
heart rate (HR), 233
ideographic, 223
and insomnia, 303
intraocular recordings, 240
linear regression model, 235
log, 304, 305
medication, 218
memory, 234
meta-analysis, 238
movement suppression, 239
nocturnal arousals, 235
non-trauma, 303
occurrence, in NREM sleep, 217
patients with TSD, 217, 221
posttraumatic, 203
prazosin, 240
prazosin vs. quetiapine, 355, 356
prodromal autonomic arousals, 236
psychological interventions, 304
psychotherapy interventions, 306
PTSD-related, 306
recording, dreams, 234
REM sleep, 235
resistance, 233
sensitivity, 238
in sleep avoidance, 203
sleep disturbance, 306
Nightmares (cont.)
sleep recordings, 234
sleep stage proportions, 234, 235, 237
suicidality, 240
symptomatic vs. non-symptomatic arousals, 234
symptoms, 303, 304
thrashing movements, 238
top-level treatment, 304
trauma, 222, 303, 304 (see also Trauma-related nightmares (TRN))
treatments, 283–285, 303

CBT-I (see Cognitive behavioral therapy for insomnia (CBT-I)) in DSM, 279
ERRT, 283
IRT, 279–283
relaxation procedures, 279
triggers, 304

Nocturnal panic
definition, 204
PLMD, 205
symptoms, panic attack, 204
vs. nightmares and panic attack, 204
Nocturnal panic attacks, 194, 196
Non-benzodiazepine GABAergic hypnotics, 339, 340
Non-rapid eye movement (NREM) sleep, 49
Normal-to-normal (NN) intervals, 257

O
Obstructive sleep apnea (OSA), 205, 243, 244, 246–248, 289
Occupational health model
cognitive appraisal training, 21
group support, 20
high-risk occupations, 20
post-deployment early intervention techniques, 21
psychological reactions, 21
response, to individual trauma, 20
training, 20
traumatic event, 20
Olanzapine, 337, 338, 342
Olfactory bridge, 320
Operation Enduring Freedom and Operation Iraq freedom (OEF/OIF), 78
μ-Opioid receptor
[11C]-carfentanil, development, 172
PET, 172
in PTSD, 173
during self-induced sadness, 172
Overshadowing the Threat of Terrorism (OTT), 367

P
Parasomnia, 215
nightmare disorder, 221
PLM, 221
therapy, 218
vs. TSD characteristics, 219, 220
Paroxetine, 326, 327, 342
Partial sleep deprivation (PSD), 69
Patient Health Questionnaire (PHQ), 50, 51
Pennebaker Inventory of Limbic Languidness, 297
Periodic limb movement disorder (PLMD), 193, 194, 205, 221
Peritraumatic Dissociative Experiences Questionnaire (PDEQ), 187
The Personality Assessment Inventory (PAI), 186, 187
Pharmacological intervention, CPT, 299
Pittsburgh Sleep Quality Index (PSQI), 196, 279, 297, 326, 327, 336–338, 340, 341, 375, 388
Polysonomography (PSG), 197, 198, 201, 204, 206, 215, 221, 399, 401
Ponto-geniculo-occipital (PGO) waves, 267
Positioning field (PF), 403
Positive airway pressure therapy (PAP-T), 243
Positron emission topography (PET)
dopaminergic dysfunction, 172
GABA_R alterations, 171
neuronal functioning, studies of, 169
opioidergic mechanisms, 172, 173
rCBF data, 169
serotonin dysfunction, 169, 170
Post-concussion syndrome (PCS), 29, 30
description, 28
and mTBI
excessive daytime sleepiness, 29
memory deficits, 29, 30
Post-CPT treatment, 299
Post-Deployment Health Assessment (PDHA), 15, 16
Post-Deployment Health Assessment Test (PDHAT), 51
Post-deployment stressors
family adjustment/relationships, 10
good sleep, 10, 11
reintegration/screening, 10
service members, injured, 10
sleep disturbances, 10
Posterior cingulate cortex (PCC), 158
and ACC, 158
DTI studies, 158
eye-movement desensitization and reprocessing therapy, 158
localized sub-regions, 158
structural properties, 158
Post-supplementary treatment, 299
Postsynaptic adrenoreceptor (AR) antagonist
alpha-1 AR, 350, 351
alpha-2 AR, 350
beta AR, 350
and NE outflow, 350
prazosin effects, 350, 351
Posttraumatic Stress Diagnostic Scale (PDS), 183
Post-traumatic stress disorder (PTSD), 13–15, 20, 30, 33, 145, 169, 180, 210, 253, 293, 303, 311, 317
actigraphy, 209
(see also Actigraphy)
assessment strategy, 15
battle fatigue and operational stress, 8
brain structural abnormalities (see Brain structural abnormalities, in PTSD)
combat-related (see Combat-related PTSD)
CPT (see Cognitive processing therapy (CPT))
definition, by DSM-5, 8, 14, 201
definition, in youth, 363
diagnostic criteria, for DSM-5, 179, 253
DSM-IV criteria, 14
eye-movement desensitization and reprocessing therapy, 158
early detection, 262
emerging trends, 21
evoked potentials, 253
environmental and genetic factors, 89
epi-genetic factors, 90, 96
gene-environment interplay, 90
human genome-wide association studies, 91–96
HRV parameters, 253
(see also Heart rate variability (HRV))
IRT (see Imagery rehearsal therapy (IRT))
hypnosis (see Hypnosis)
military experiences, 13
molecular genetic studies, 90, 91
NDR (see Nightmare deconstruction and reprocessing (NDR))
neurologic dysfunction, investigation (see Positron emission tomography (PET))
outcomes, high-risk occupations, 13
pathological outcome, 179
pharmacologic reduction, CNS noradrenergic activity, 354
prevalence, 89
in Afghanistan and Iraq, 14, 15
in police officers and firefighters, 13
in US Vietnam, 14
psychotherapy, 82
quantitative EEG and neuroimaging, 230
quantitative genetic studies, 90
related sleep disturbances, 89
second sleep-related concern, 89
and sleep
diagnosis, 20
hyperarousal and irritability, 30
pre-deployment sleep problems, 20
problems, 145
reexperiencing of traumatic events, 30
REM, 89
role, in development, 20
systems, 377
soldiers and veterans, 8
suicidal behavior, 77
symptoms, 201, 277
treatments, 283–285
twin studies, 90, 91
War zone-related (see War zone stressors)
Posttraumatic Stress Disorder Symptom Scale (PTSDS), 375
Prazosin, 307, 351–356
adverse effects, 356
in alcohol use disorder
preclinical studies, 354, 355
with and without comorbid PTSD, in humans, 355
in postconcussive headaches, 354
and postsynaptic alpha-1 AR, 354
vs. quetiapine, for nighttime PTSD symptoms, 355, 356
RCTs, 349
CAPS, 352
CGIC, 352
crossover study, in civilian trauma PTSD participants, 352
double-blind placebo-controlled crossover study, 352
and doxazosin, 353
and hydroxyzine, 353
midmorning prazosin dose, 353
military veterans and civilian trauma, victims, 353
parallel group study, 352
studies, publication, 351–352
standing systolic BP, 353
therapeutic effects
“first-dose” hypotension, 356
pretreatment standing systolic BP, 356
REM sleep, normalization, 356
Prefrontal cortex (PFC), 266
dynamic changes, 159
functional neuroimaging studies, 159
pediatric PTSD studies, 159
structural changes, 159
subdivisions, 158
VBM structural studies, 159
Pregabalin, 336, 337
Pre/Post Deployment Study (PDDS), 96
Primary Care PTSD Screen (PC-PTSD), 186
Prolonged exposure (PE), 295, 297, 311
Propranolol, 132, 133, 139
in alcohol preferring (P) rats, 355
beta AR antagonist, 350
open-label treatment, 350
and prazosin, 351
prophylaxis study, in rats, 354
tachycardia and palpitations response, 356
Protein kinase M zeta (PKMC), 130, 137, 141
Psychiatric Epidemiology Research Interview (PERI), 389
The Psychiatric Genetics Consortium for PTSD (PGC-PTSD), 96
Psychoanalytic enunciation analysis (PEA)
definition, 398
in dream narrative, 407
enunciation, 398
imaginary mode, 398
method of, 405, 406
painful emotions/psychic material, 407
pre-reflected and pre-verbal processes, 398
symbolic mode, 398
symbolization, assessing level, 405–407
torture survivors dreams, 400, 401
Psychobiology, posttraumatic stress disorder, 396
Psychodynamic and Gestalt dream theories, 311
Psychological resiliency, in military, 53, 54
assessment, sleep, 54, 55
Battlemind training, 52
Comprehensive Soldier Fitness, 53
definition, 52
progressive requirements
knowledge and skills, 53
model, 53, 54
physiological needs, 53
resilience, 54
social support, 53
resiliency, described, 52
restful sleep, 53
social support and hardiness, 52
TFF, 52
Psychotherapy interventions, 277, 279, 286–289
CPT, 299
evidence-based interventions (see Evidence-based interventions)
PTSD, 279
symptoms, 279
treatments, nightmares (see Nightmares)
sleep (see Sleep interventions)
suicidal behavior, 81, 82
PTSD Checklist (PCL), 182–184
PTSD Dream Rating Scale, 352
PTSD Symptom Scale Interview Version (PSS-I), 181
Q
Quetiapine, 337, 338
second-generation antipsychotic drug, 355
vs. prazosin, for nighttime PTSD symptoms, 355, 356
R
Randomized controlled trials (RCTs), 278, 279, 294, 295, 351
Rapamycin
memory reconsolidation process, intervention, 135
mTOR, early post-stressor microinjection, 128
Rapid eye movement (REM) sleep, 267
alpha-1 AR modulation, 351
awake state, REM vs. non-REM, 352
declarative memory consolidation frameworks and data, 267
PGO waves, 267
theta rhythm, 267
prazosin effect, 352, 356
Reconsolidation process, memory anisomycin, post-reminder administration, 135
behavioral responses, 135
corticosterone, post-reminder administration, 135, 136
long-term repeated intervention, 136, 137
rapamycin, post-reminder administration, 135
temporarily de-stabilized state, 135
Regional cerebral blood flow (rCBF), 169
Reintegration, soldiers, 10
Relapse prevention, 294
Relaxation training, 318, 319
Reparation claims, 386
age, gender and date, assessment, 387
anxiety symptoms, 386
nightmares, 387
poor sleep with nightmares, 386
PTSD DSM-III-R diagnosis, 387
Repetitive posttraumatic nightmares, 395
Research Domain Criteria (RDoC) project, 227
Respiratory effort-related arousals (RERA), 243
Response to Stressful Experiences Scale (RSES), 54, 55
Restful sleep, 49, 53, 55
Returning veterans, 205
Revised Civilian Mississippi Scale (RCMS), 185
Revivification, 319
Risperidone, 337, 342
Rostral anterior cingulate cortex (rACC), 111, 112, 115–118
Rumination, 319, 321
Schizophrenia, 80
SCID-CV, 396
Screening measures, PTSD instruments, 186
large-scale traumatic events, 185
PC-PTSD, 186
SPAN, 186
TSQ, 186
Second Lebanon War, 367
Second World War (WWII), 381, 386–388, 390, 391, 393
Selective serotonin reuptake inhibitors (SSRIs) cessation, 326
citalopram and escitalopram, 327
fluoxetine, 326
fluvoxamine, 327
paroxetine, 326
REM sleep, 326
sertraline, 326
Sleep changes actigraphy, 204
brain imaging, 204
common comorbid sleep disorders, 205
co-sleeping, 207
insomnia, 202
long-term psychotherapy, 206
nightmares, 203
nocturnal panic, 204
prevalence, sleep disturbance, 201, 202
prolonged sleep onset, 206
PSG, 204
psychiatric and medical comorbidity, 204, 205
Sleep deprivation (SD) chronic, 70
and circadian misalignment, 72
during military operations, 70
performance and motor activities, 70
post-stressor intervention, consolidation process, 133, 134
PSD, 69
sleep inertia, 69
traditional watch schedules, 71
vigilance performance, 70
Sleep deprivation-impaired consolidation processes, 139
Sleep disorders, 202
Sleep-disordered breathing (SDB), 194, 196, 197, 243
adherence rates and outcomes, 248
adult population, 243
apneas and hypopneas, 243
assessment, 246, 247
clinical perspectives, 247
consensus/research findings, 248
co-occurring conditions, 249
medical and psychiatric comorbidity, 249
OSA (see Obstructive sleep apnea (OSA))
outcomes, 248
PAP-NAP procedure, 249
PAP-T, 243
polysomnography epochs, 243, 244
of posttraumatic insomnia, 243
prevalence rates, 247
PSG, 246
research recommendations, 250
symptoms/diagnoses, 243
treatment, 248
Sleep disorders, medications, 326, 330, 337
agomelatine, 330
alpha-1 and alpha-2, 329
anticonvulsants (see Anticonvulsants)
antipsychotics (see Antipsychotics)
buspirone, 340
cannabis and synthetic cannabinoid, 341
classes, 326
clonidine, 338, 339
cortisol and mifepristone, 340
cyproheptadine, 340
duloxetine, as SNRIs, 327
guanfacine, 339
HSD and HSND, 386
MAOIs see Monoamine oxidase inhibitors (MAOIs), 328
mirtazapine, 330
nefazodone, 330
nightmares, 386
non-benzodiazepine GABAergic hypnotics, 339, 340
SSRIs (see Selective serotonin re-uptake inhibitors (SSRIs))
survivor syndrome, 382
TCAs, 328
trazodone, 329, 330
venlafaxine, as SNRIs, 327
vortioxetine, 330
Sleep disturbance, 194
assessment and treatment, 49, 50
cause, 317
concentration, difficulty, 28, 29
core feature, PTSD, 201–202
depression, 28
described, 215
and disturbed sleep, 50
fatigue, 26, 27
hyperarousal, 29
insomnia, 28, 194, 317
measurements, sleep, 193
MHAT reports (see Mental Health Advisory Team (MHAT) reports)
military deployment, 60
natural history, types and causes, in military, 55
neuroimaging studies, 193
nocturnal panic attacks/somnambulism, 194
PLMD, 194
prevalence, in PTSD, 201, 202
PSG, 197
PTSD and mTBI/PCS symptoms, 26
PTS symptoms, 374
SDB, 194
self-reported symptoms, 59
sleep onset latency, 60
surveys, 60
symptoms, 49
TASD, 194, (see also Trauma associated sleep disorder (TSD))
TRN, 215
TSD, 215
“unique” symptoms, mTBI/PCS, 26, 27
Sleep duration
and poor sleep quality, 375, 376
variability, 376
war trauma, exposure to, 377
Sleep dynamic therapy, 306
Sleep interventions, 286–289
CPAP machines, 289
distress, 286
in DSM-5, 286
insomnia, 286
models, PTSD, 286
nightmares, 286
OSA, 289
PTSD treatments
active-duty service members, 287
CBT, 288
clinical practice, 288
CPT and PE, 287
EMDR, 287
insomnia, 286
memories, 287
nightmares, 286, 287
non-validated measure, 287
perpetuating factors, 288
psychological treatments, 286
RCTs, 288
secondary symptom, 288
sleep disturbances, 287, 288
sleep-focused treatment, 288
sleep outcomes, 286, 287
Spielman’s behavioral model, 288
symptoms, 288
types of patients, 289
validated measures of sleep outcomes, 288
Sleep laboratory procedure, 391–393, 397
Sleep latency, 352
Sleep medication/alcohol usage, 304
Sleep phenotypes
definition, 97
epigenetic modifications, 99
genetics of, 97
GWAS, 99
molecular genetic studies, 97–99
twin studies, 97
Sleep problems
algorithm for treatment, 342, 343
cannabis use, 341 (see also Sleep disorders, medications)
studies and outcome, on PTSD and sleep, 330–335
TCAs usage, 328
topiramate effect, 336
vortioxetine use, 330
Sleep quality, 375, 376
adjunctive treatments, 378
children exposed to war into adulthood
chi-square test, 376
confirmatory factor analysis, 375
Sleep quality (cont.)
exposure level to trauma and violence, 375
initial assessment, 375
LEC, 375
measure of exposure, validating, 376
mediation model, 376
PSQI, 375
PTSDS, 375
recruitment sources, 375
single sleep factor model, 376
Gulf War in childhood, 374
longitudinal research, 378
nonpharmacological interventions, 378
self-report measures, 196
and sleep duration, 376
Sleep-related breathing disorders (SRBD), 205
Sleep restriction, 284
Sleep variables, 304
Slow-wave sleep (SWS), 227–229, 231, 266
declarative memory consolidation
active system consolidation theory, 266
first half of the night, 266
hippocampus, 266
LTP and LTD processes, 266
memory traces, 266
PFC, 266
REM-rich second half of the night, 266
sharp-wave ripple, 266
signal-to-noise ratio, 266
stages of sleep, 266
synaptic homeostasis theory, 266
synchronization, 266
Social Adjustment Scale, 297
Social support, 53, 81
Soldier Combat and Well-Being Model, 62
Sonnambulism, 194
Spielberger State-Trait Anxiety Inventory, 297
Split screen technique, 320
Standing systolic blood pressure (BP), 353
State-Trait Anger Expression Inventory, 297
Statistical Manual of Mental Disorders (SCID), 91
STOP-BANG, 196
Stress response
phases, 7, 8
on relationships, 9
Stressors, modern warfare
composition, military force, 5, 6
operational tempo, 6, 7
pre-deployment stressors, 7
public interest, 7
Structured Clinical Interview for DSM-IV (SCID), 181, 182
Structured Interview for PTSD (SIP), 182
CAPS, 180, 181
CIDI, 182, 185
to clinical judgment, 180
PSS-I, 181
SCID, 181
SIP, 182
Subjective Units of Distress Scale (SUDS), 312
Substance abuse, 205
Suicidal behavior, 8, 9, 79, 80
comorbid psychiatric conditions
alcohol and drug abuse disorders, 80
anxiety disorders, 80
BPD, 80
and primary psychotic disorders, 79
PTSD and mood disorders, 79
coping mechanisms, 81
general and combat-exposed populations, 77, 78
prevalence, 77
prevention, strategies, 82
psychopharmacological intervention, 82
psychotherapy, 81
risk factors, 77
risk of death, 78, 79
social support, 81
and trauma, 77, 81
Suicidal ideation
and PTSD, 78
in Vietnam combat veterans, 78
Suicide attempt
ESEMED, 78
and PTSD, 78
Suprachiasmatic nuclei (SCN), 98
Surface EEG indicators, 266
Survivor syndrome, 382
SWAT team, 314, 315
Symbolization, 396, 405
Synaptic homeostasis theory, 266, 267
Synthetic cannabinoid, 341
T
Terrorism, 9
Theta rhythm, 267
Thioridazine, 338
Tiagabine, 336
Tolloid-like 1 gene (TLL1), 96
Topiramate, 336
Toronto Alexithymia Scale-20, 297
Torture survivors, study
analyse dream reports, 407
clinical everyday practice, 407
coding, dreams, 400
evaluation, dreams group, 400
PEA analysis, 400, 401
Subject 308, 401–403
subjects, 396
threatening situation, 403
WSAQ, 397
Total Force Fitness (TFF), 52, 53
Total sleep deprivation (TSD), 69
Trauma-associated sleep disorder (TASD), 193, 194, 197, 215,
217–222
clinical characteristics, 216, 218
associated illnesses and comorbid sleep disorders, 218
autonomic hyperarousal, 218
clinical course, 218
DNB, 218 (see also Disruptive nocturnal behaviors (DNB))
nightmares, 217
onset/precipitating factors, 217
patient demographics, 217
REM sleep without atonia, 218
therapy, 218
diagnostic polysomnography, 215
and emotional impairment, 81
neurobiological hypothesis
amygdalar projections, 222
in normal sleep, 221
sleep deprivation, 222
Index

trauma, 221
traumatic nightmares, 222
vs. parasomnias
characteristics, 219
nightmare disorder, 221
PLM, 221
polysomnography, 221
REM sleep behavior disorder, 219, 220
proposed diagnostic criteria, 217
PSG-documented abnormalities, 216
recognition, 215
restless sleep and disturbing nightmares, 215
and suicidal behavior, 81
TSD (see Trauma associated sleep disorder (TSD))
Trauma-content nightmares
“adrenaline storm”, 350
feature, combat PTSD “sleep disturbance”, 349
prazosin effects, 351, 356
psychotropic medications, 349
sleep disturbance and recurrent, 349
Trauma-focused cognitive behavioral therapy
(TF-CBT), 366
Trauma-Related Guilt Inventory (TRGI), 188, 296, 297
Trauma-related nightmares (TRN), 304
characteristic features, 216
and DNB, 216
dream content, 221
sleep disturbances, 215
and TSD, 215
Trauma-related sleep disturbance, 188, 297, 298
Trauma Screening Questionnaire (TSQ), 186
Trauma Symptom Inventory (TSI), 185, 187
Traumatic brain injuries (TBI), 205, 295
in modern warfare, 10
service members, 10
Traumatic dreams
combat operations, 396
distressing dreams, 395
ethnic cleansing, 396
posttraumatic nightmares, 395
Traumatic events, 5
Traumatic memories, 139
Trazodone, 329, 330, 341, 342
Tricyclic antidepressants (TCAs)
clomipramine, 328
clonidine, 328
desipramine, 328
imipramine, 328
trimipramine, 328
Twin studies
PTSD, 90, 91
sleep phenotypes, 97

U
Upper airway resistance syndrome (UARS), 243, 244

V
Venlafaxine, 326, 327
Video teleconferencing group, 295
Violence, 9
Vocational rehabilitation, 294
Vortioxetine, 330

W
Waking life events, 313
War-exposed youth, 366, 367
acute vs. chronic exposure, 365
adolescents, 364
challenges, treatment, 368
ecological perspective, treatment, 368, 369
indirect exposure, 365, 366
infants and toddlers, 363, 364
non-evidence-based interventions, 368
psychosocial treatments
family therapy, 367
individual, 366
school-based, 367
school-age children, 364
treatment, sleep disturbances, 367
War-related exposure
mediation model, exposure, 376
on poor sleep quality, 376
PTS symptoms, 374, 377
sleep problems, 373
War-Stressors Assessment Questionnaire (WSAQ), 397
War trauma
among adults, 373
assessments, 378
childhood exposure, 373
depression symptoms, 374
emotional symptoms, causes of, 5
history of, 5
psychological responses, 5, 9
sleep problems, 377
War zone stressors, 33–38
cognitive appraisal, gender differences, 38, 39
combat exposure
development, 33
levels of, 34
MST, 34
type of, 34
coping styles, gender differences, 39
mental health impact, 33
mental health outcomes, gender differences, 35, 36
neurobiological correlates, gender differences, 39
response to treatment, gender differences, 40
risk and resiliency factors
developmental relationships, 35
multiple deployments, 34
post-deployment interpersonal functioning, 35
prior trauma, 34, 35
roles, female military, 33
symptomatology, gender differences
acute stress disorder (ASD), 37
distress level, 37
masculinity and femininity, 37
motor vehicle accidents (MVAs), 36
self-report and objective data, 37
sleep, 38
traumatic experiences, civilian, 37
Women, in war zone
acute stress disorder (ASD), 37
to civilian traumas, 33
distress, rate, 37
risk factors, 33
roles, 33
traumatic responses, 37
World Mental Health Survey (WMHS), 390
Written account-only (WA) condition, 278, 295

Y
Youth, PTSD, 363, 364
  acute vs. chronic exposure, 365
  definition, 363
  indirect exposure, 366

separation and loss, 364, 365
symptoms, 363
trauma and sleep, 364
treatment, sleep disturbances, 368
war-affected
  adolescents, 364
  infants and toddlers, 363, 364
  school-age children, 364